Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 4

The DOI matches its Crossref record.

Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients With Advanced Liver Disease

Shenoy, Abhishek, Jasty, Venkata Sai, Uttal, Sarah, Nasser, Sarah, Winder, Gerald Scott, Mellinger, Jessica, Fontana, Robert J. · 2025 · American Journal of Gastroenterology

Abstract

The number of alcohol use disorder patients with mild (n = 101) and severe alcoholic liver disease (n = 112) increased between 2013 and 2023 ( P = 0.06). Naltrexone was prescribed in 65%, acamprosate in 26%, and disulfiram in 9%. Internal medicine providers were the most frequent prescribers (51%), followed by psychiatry (30%) and gastroenterology/hepatology (9%) ( P = 0.001). Duration of use was longest with naltrexone compared with acamprosate and disulfiram (360 vs 251 vs 190 days, P = 0.032). The rate of alcohol use disorder medication discontinuation for adverse events was similar in both groups (14% vs 12%). Naltrexone, acamprosate, and disulfiram are increasingly being prescribed in American patients with mild and severe alcohol-related liver disease with similar tolerability and efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000003328

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 9

  1. Kranzler, 2018, Diagnosis and pharmacotherapy of alcohol use disorder: A review, JAMA, 320, 815, 10.1001/jama.2018.11406 · DOI · Paper page
  2. Mintz, 2021, A cascade of care for alcohol use disorder: Using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care, Alcohol Clin Exp Res, 45, 1276, 10.1111/acer.14609 · DOI
  3. Lanz, 2023, Disulfiram: Mechanisms, applications, and challenges, Antibiotics (Basel), 12, 524, 10.3390/antibiotics12030524 · DOI
  4. Nielsen, 2022, Treatment of alcohol use disorder in patients with liver disease, Curr Opin Pharmacol, 62, 145, 10.1016/j.coph.2021.11.012 · DOI
  5. Weinrieb, 2001, Alcoholism treatment after liver transplantation: Lessons learned from a clinical trial that failed, Psychosomatics, 42, 110, 10.1176/appi.psy.42.2.110 · DOI
  6. Han, 2021, Use of medications for alcohol use disorder in the US: Results from the 2019 national survey on drug use and health, JAMA Psychiatry, 78, 922, 10.1001/jamapsychiatry.2021.1271 · DOI
  7. Mellinger, 2021, Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic, J Subst Abuse Treat, 130, 108396, 10.1016/j.jsat.2021.108396 · DOI
  8. Im, 2021, Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: A survey from the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group, Clin Gastroenterol Hepatol, 19, 2407, 10.1016/j.cgh.2020.10.026 · DOI
  9. Jurimae, 2021, Serum sclerostin and cytokine responses to prolonged sculling exercise in highly-trained male rowers, J Sports Sci, 39, 591, 10.1080/02640414.2020.1837428 · DOI

Cited by

See all 4

Metadata

Authors
Shenoy, A., Jasty, V. S., Uttal, S., Nasser, S., Winder, G. S., Mellinger, J., & Fontana, R. J.
Affiliations
  • Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA;
  • Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA;
  • Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.
Venue
American Journal of Gastroenterology
Published
2025-01-21
Volume
120
Issue
11
Pages
2576-2582
ISSN
  • 0002-9270
  • 1572-0241
Cited by
4
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients With Advanced Liver Disease. https://app.cochat.ai/papers/10.14309/ajg.0000000000003328
The paper
Shenoy, A., Jasty, V. S., Uttal, S., Nasser, S., Winder, G. S., Mellinger, J., & Fontana, R. J. (2025). Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients With Advanced Liver Disease. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000003328

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.